Differences

This shows you the differences between two versions of the page.

--- philippe_de_wals [2022/04/21 08:29]
liam
+++ philippe_de_wals [2022/04/21 10:10] (current)
liam [Research]
@@ Line 1: / Line 1: @@
 ====== Philippe De Wals ======
-{{ ::philippe-de-wals.jpeg?200|}}
+{{ ::philippe-de-wals.jpeg?150|}}
-Dr. **Philippe De Wals** is a Canadian epidemiologist and [[public health]] specialist based in Quebec City, Quebec. He is notable in the [[COVID-19 pandemic]] due to his role in approving [[COVID-19 vaccines]] in Canada as a member of the [[National Advisory Committee on Immunization]] (NACI).
+Dr. **Philippe De Wals** is a Belgian-Canadian epidemiologist and [[public health]] specialist based in Quebec City, Quebec. He is notable in the [[COVID-19 pandemic]] due to his role in approving [[COVID-19 vaccines]] in Canada as a member of the [[National Advisory Committee on Immunization]] (NACI).
+In 1990, De Wals was awarded the [[Jean Van Beneden Prize]] in recognition of his excellent work in the [[public health]] field, and in 2005, he was elected to the [[Royal Academy of Medicine of Belgium]].
+===== Education =====
+De Wals gained his Medical Degree and a Doctorate in Public Health in his home country of [[Belgium]], at the [[Louvain Catholic University]].
 ===== Career and Affiliations =====
+De Wals is a medical advisor to the [[Institut national de santé publique du Québec]]. He is a working group member for [[Vaccines Together]].((//Philippe De Wals.// Vaccines Together. Retrieved April 21, 2022, from https://www.vaccinestogether.org/philippe_de_wals))
+==== EUROCAT ====
+Between 1980 and 2000 he worked as an epidemiologist for [[EUROCAT]], a European network of population-based registries for the epidemiological surveillance of congenital anomalies.
+==== University of Sherbrooke ====
+In 1990, De Wals moved to [[Canada]] and became the Head of the Department of Community Health Sciences at the [[University of Sherbrooke]]. He is a researcher at the [[Sherbrooke University Hospital Centre]].
+=== University of North Carolina at Chapel Hill ====
+In 1997, he was appointed visiting Professor at the School of Public Health at the [[University of North Carolina at Chapel Hill]] in the [[United States of America]].
 ==== Laval University ====
-De Wals is a professor at the Department of Social and Preventive Medicine at [[Laval University]].((//Philippe De Wals | Researchers.// Evaluation Platform on Obesity Prevention. Retrieved April 20, 2022, from https://evaluation-prevention-obesite.ulaval.ca/en/researchers/philippe-de-wals/))
+De Wals is a professor at the Department of Social and Preventive Medicine at [[Laval University]].((//Philippe De Wals | Researchers.// Evaluation Platform on Obesity Prevention. Retrieved April 20, 2022, from https://archive.ph/o3K8K))
+==== Quebec University Hospital ====
+De Wals is a member of the research center at [[Quebec University Hospital]].
+==== Quebec Heart and Lung Institute ====
+In 2011, he was appointed as Scientific Director of the Evaluation Platform on Obesity Prevention at the [[Quebec Heart and Lung Institute]].
 ==== Public Health Agency of Canada ====
 De Wals is a member of the [[National Advisory Committee on Immunization]] (NACI), where he participated in the approval of [[COVID-19 vaccines]] in Canada.((//National Advisory Committee on Immunization (NACI): Membership and representation. //(2020, December 18). Wayback Machine; Government of Canada. https://web.archive.org/web/20201218222110/https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/naci-membership-representation.html))
+===== Research =====
+De Wals has received research grants and travel reimbursement from [[pharmaceutical_companies:GlaxoSmithKline]], [[pharmaceutical_companies:Merck]], [[pharmaceutical_companies:Novartis]], [[pharmaceutical_companies:Pfizer]], and [[pharmaceutical_companies:Sanofi]]. Specifically, he benefited from unrestricted research grants from GlaxoSmithKline, Pfizer, and Sanofi, for whom he has also served as scientific advisor.((De Wals, P. (2019). //Epidemiology and Control of Meningococcal Disease in Canada: A Long, Complex, and Unfinished Story.// Canadian Journal of Infectious Diseases and Medical Microbiology, 2019, 1–11. https://doi.org/10.1155/2019/8901847)) ((De Wals, P. (2015, October 10). //Economic Analysis of Pneumococcal Vaccination for Elderly Adults in Quebec: Forecasting Invasive Pneumococcal Disease (IPD) Rates of and Serotype Distribution.// Confex; Infectious Diseases Society of America. https://archive.ph/gxSeC))
+Additional funding has come from the [[Public Health Agency of Canada]] and the [[Quebec Ministry of Health and Social Services]].((Cléophat, J.-E., Le Meur, J.-B., Proulx, J.-F., & De Wals, P. (2014). //Uptake of pneumococcal vaccines in the Nordic region of Nunavik, province of Quebec, Canada.// Canadian Journal of Public Health, 105(4), e268–e272. https://doi.org/10.17269/cjph.105.4315))
+In 2021, De Wals participated in the The Pneumococcal Serotype Replacement and Distribution Estimation ([[PSERENADE]]) Project, funded by the [[Bill & Melinda Gates Foundation]] as part of the [[World Health Organization]] [[Pneumococcal Vaccines Technical Coordination Project]].((Deloria Knoll, M., Bennett, J., Garcia Quesada, M., Kagucia, E., Peterson, M., Feikin, D., Cohen, A., Hetrich, M., Yang, Y., Sinkevitch, J., Ampofo, K., Aukes, L., Bacci, S., Bigogo, G., Brandileone, M.-C., Bruce, M., Camilli, R., Castilla, J., Chan, G., & Chanto Chacón, G. (2021). //Global Landscape Review of Serotype-Specific Invasive Pneumococcal Disease Surveillance among Countries Using PCV10/13: The Pneumococcal Serotype Replacement and Distribution Estimation (PSERENADE) Project.// Microorganisms, 9(4), 742. https://doi.org/10.3390/microorganisms9040742))